Overdiagnosis and overtreatment of breast cancer: Microsimulation modelling estimates based on observed screen and clinical data

Breast Cancer Research

Volumn 8, Issue 1, 2005, Pages

  de Koning, Harry J ^a   Draisma, Gerrit ^a   Fracheboud, Jacques ^a   de Bruijn, Arry ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 69849106592     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1369     Document Type: Review

References (18)

1. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE: Long-term effects of mammUgraphy screening: updated overview of the Swedish randomised trials. Lancet 2002, 359:909-919. Erratum in Lancet 2002, 360:724.
2. Otto SJ, Fracheboud J, Looman CWN, Broeders MJM, Boer R, Hendriks JHCL, Verbeek ALM, de Koning HJ and the National Evaluation Team for Breast Cancer ScreeningInitiation of population- based mammography screening in Dutch municipalities and effect on breast-cancer mortality: A systematic review. Lancet 2003, 361: 1411-1417.
3. Olsen AH, Njor SH, Vejborg I, Schwartz W, Dalgaard P, Jensen MB, Tange UB, Blichert-Toft M, Rank F, Mouridsen H, Lynge E: Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. Br Med J 2005, 330: 220-224.
4. Rijnsburger AJ, van Oortmarssen GJ, Boer R, Draisma G, To T, Miller AB, de Koning HJ: Mammography benefit in the Canadian National Breast Screening Study-2: A model evaluation. Int J Cancer 2004, 110:756-762.
5. de Koning HJ: Assessment of nationwide cancer-screening programmes - Commentary. Lancet 2000, 355:80-81.
6. van Oortmarssen G: Evaluation of maAs screening for cancer: a model-based approach. PhD Thesis. Department of Public Health, Erasmus Universiteit, Rotterdam; 1995.
7. Fracheboud J, Otto S, Dijck JAAM van, Broeders MJM, Verbeek ALM, de Koning HJ, and the National Evaluation Team for Breast Cancer Screening: Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer 2004, 91 861-867.
8. Netherlands Cancer Registry: Trends in breast cancer incidence 2002 Utrecht; 2005.
9. Groenewoud JH, Pijnappel RM, van den Akker-van Marle ME, Birnie E, Buijs-van der Woude T, Mali WPTM, de Koning HJ, Buskens E: Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy. Br J Cancer 2004, 90:383-392.
10. Boer R, Plevritis S, Clarke L: Diversity of model approaches for breast cancer screening: A review of model assumptions by the Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups. Stat Meth Med Res 2004, 13:1-14.
11. Day NE, Walter SD: Simplified models of screening for chronic disease: Estimation procedures from mass screening programmes. Biometrics i 1984, 40:1-14.
12. van Oortmarssen GJ, Boer R, Habbema JD: Modelling issues in cancer screening. Stat Methods Med Res i 1995, 4:33-54.
13. Day NE, Walter SD, Tabar L, Fagerberg CJG, Collette HJA: The sensitivity and lead time of breast cancer screening: A comparison of the results of different studies. In Screening for Breast Cancer. Edited by Day NE, Miller AB. Toronto: H Huber Publishers; 1988:105-109.
14. Verbeek ALM, Straatman H, Hendriks JHCL: Sensitivity of mammography in Nijmegen women under age 50: Some trials with the Eddy model. In Screening for Breast Cancer. Edited by Day NE, Miller AB. Toronto: H Huber Publishers; 1988:29-32.
15. Fracheboud J, Groenewoud JH, Boer R, Draisma G, de Bruijn AE, Verbeek ALM, de Koning HJ: The upper age limit of 75 for breast cancer screening: Results from the Dutch nation-wide screening programme. Int J Cancer, in press.
16. Duffy SW, Tabar L, Vitak B, Day NE, Smith RA, Chen HH, Yen MF: The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. Eur J Cancer 2003, 39:1755-1760.
17. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al.: Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000, 355:528-533.
18. de Haes JC, de Koning HJ, van Oortmarssen GJ, van Agt HM, de Bruyn AE, van der Maas PJ: The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer i 1991, 49 538-544.